.Merck defeats earnings requirements, rears sales expectation on strong need for leading drugs like Keytruda CNBCMerck & Co. (MRK United States) Defeats Revenue Estimates as Keytruda Sales Increase BloombergMerck Stock: Pharma Titan Posts Powerful Outcomes, However Overview Falls Short Financier's Organization DailyMerck Announces Second-Quarter 2024 Financial Outcomes Yahoo FinanceMerck defeats revenue and also sales desires in the middle of Keytruda strong point, but offers mixed full-year expectation MarketWatch.